Maxigesic

Phase 3Small molecule

YYonsei University

Maxigesic is one of 39 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Stomach NeoplasmsNot yet recruiting

Breast CancerPreclinical

Active, not recruiting

Stomach NeoplasmsPhase 3

Not yet recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Maxigesic

YYonsei University

Phase 3

1 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Duragesic-100

CCephalon

Preclinical

2 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Tricor

JJagotec

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Ablavar

LLantheus Medical Imaging

Preclinical

2 10

Naltrexone/bupropion

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

ApprovedNot yet recruiting

Stomach Neoplasms

NCT07687394

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Analgesic Efficacy of Maxigesic in Breast Cancer Surgery

Recruiting·YYonsei University·N/A·NCT06174363·84 enrolled

Stomach Neoplasms1 trial

A Phase IV, Multicenter, Double-blind, Randomized Controlled Trial to Evaluate the Superiority of Maxigesic® Over Standard Analgesia in Patients Undergoing Radical Gastrectomy

Not yet recruiting·YYonsei University·Approved·NCT07687394·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Maxigesic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Maxigesic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Maxigesic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: YYonsei University

Maxigesic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Breast Cancer1 trial

Stomach Neoplasms1 trial

References

Drug Info

Quick Facts

Related News